Rufinamide is an antiepileptic drug that exerts therapeutic effects by regulating sodium channel activity. Its mechanism of action and drug interactions require special attention to ensure rational clinical use.

1. Effect of action

(1) Mechanism of action

Lufenamide reduces the frequency of epileptic seizures, especially in Lennox Gastaut syndrome, by prolonging the inactive state of sodium channels and inhibiting high-frequency neuronal discharges.

(2) Clinical efficacy

It can reduce the frequency of tonic clonic seizures and absence seizures, and is effective for both partial and generalized seizures. It is usually used as an adjunct therapy for refractory epilepsy patients.

2. Drug interactions

(1) The impact of liver drug enzymes

CYP3A4 inducers (such as carbamazepine) may reduce the blood concentration of lufenamide and their efficacy needs to be monitored; CYP3A4 inhibitors have a minor impact and usually do not require dose adjustment.

(2) Antiepileptic drugs

Combined use with valproic acid may increase the blood concentration of Lufenamide and should be reduced as appropriate; Combined use with phenytoin sodium may reduce efficacy and requires close monitoring of seizure frequency.

(3) Other drugs

Combined use with oral contraceptives may reduce contraceptive effectiveness, and it is recommended to use additional contraceptive measures; The combination with warfarin requires strengthened INR monitoring to prevent fluctuations in anticoagulant efficacy.

3. Special precautions

(1) Abnormal liver function

Patients with moderate to severe liver injury need to reduce their use as drug metabolism may be hindered, increasing the risk of adverse reactions.

(2) Drug monitoring

It is recommended to regularly monitor blood drug concentration during treatment, especially when combined with other antiepileptic drugs, with a target concentration range of 10-40mg/L.